27 March 2024 - Approval based on CAPItello-291 results which showed Truqap plus Faslodex reduced the risk of disease progression ...
27 March 2024 - First and only RSV preventive option for broad infant population authorised for use in Japan. ...
26 March 2024 - Adzynma (apadamtase alfa/cinaxadamtase alfa) is the first and only recombinant ADAMTS13 enzyme replacement therapy for people with congenital ...
26 March 2024 - MHLW approval makes Vyloy the first and only CLDN18.2-targeted therapy approved in the world. ...
15 February 2024 - Priority review designation is based on results from the Phase 3 EV-302 trial, which found enfortumab vedotin ...
16 February 2024 - Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to ...
15 February 2024 - To address and maintain the financial sustainability of the national insurance system, the Government rolled out several ...
8 February 2024 - Crovalimab, the fifth Chugai originated global drug, approved for the first time in the world. ...
26 January 2024 - Eisai announced today that it has submitted a new drug application for ultra high dose mecobalamin (development ...
31 January 2024 - Submission for second indication of Sakigake designated Ezharmia based on VALENTINE-PTCL01 results in patients with relapsed ...
20 January 2024 - The Progeria Research Foundation marks significant achievement as Zokinvy (lonafarnib) receives Japanese approval for the treatment ...
18 January 2024 - Eisai announced today that it has obtained marketing authorisation approval from the Japanese Ministry of Health, ...
18 January 2024 - Vyvdura provides patients with option for self-administration. ...
19 January 2024 - Approval of first in class, oral, factor D inhibitor based on ALPHA Phase 3 trial in ...
27 December 2023 - The extended approval for bimekizumab in Japan follows its first approval in January 2022 for plaque ...